Search clinical trials for: AMG 199

Total 4980 results

Amgen

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Kyowa Kirin Co., Ltd.

Completed

Safety Study of AMG 531 in Japanese Subjects With ITP

Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Amgen

Terminated

First-in-Human Study to Evaluate AMG 579 in Healthy Subjects and Patients With Stable Schizophrenia

Schizophrenia

United States
Amgen

Completed

Phase II Study to Evaluate the Efficacy of AMG 317

Asthma
Alexza Pharmaceuticals, Inc.

Completed

Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome

Cyclic Vomiting Syndrome

United States
Seoul National University Hospital
Ministry of Food and Drug Safety, Korea

Completed

Pharmacokinetic-pharmacodynamic Analysis of Sugammadex in Children

Anesthesia, General | Neuromuscular Blockade

Korea, Republic of
NantCell, Inc.

Terminated

QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

Sarcoma | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Metastatic Cancer | Solid Tumors | Locally Advanced
Jiangsu Kanion Pharmaceutical Co., Ltd
Beijing Bionovo Medicine Development Co., Ltd.

Completed

A Pilot Study for Ginkgolides Meglumine Injection Skin Testing.

Allergy

China
Seoul National University Hospital
Ministry of Food and Drug Safety, Korea

Completed

Pharmacokinetic-pharmacodynamic Analysis of Sugammadex for Conventional Reversal in Children

Anesthesia, General | Neuromuscular Blockade

Korea, Republic of
Amgen

Completed

Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

Cardiovascular Disease

United States, Australia, Netherlands, Canada, Denmark, Iceland, Japan
Amgen

Completed

Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim

Idiopathic Thrombocytopenic Purpura

Italy, United States, Germany, Czechia, United Kingdom, Australia, Spain, Poland, France
MedImmune LLC
Amgen

Completed

A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome

Primary Sjögren's Syndrome

United States, Sweden, France, United Kingdom
Amgen

Terminated

Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease

Chronic Graft Versus Host Disease cGVHD

United States, Japan, France, Belgium
Amgen

Completed

Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

Thrombocytopenic Purpura
Boehringer Ingelheim

Completed

Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients

Multiple Myeloma

Germany, France
Cytokinetics

Withdrawn

Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients

Heart Failure
Amgen

Completed

Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Belgium, Canada, Denmark, Italy, Hungary, Germany, Switzerland, Netherlands, Australia, Russian Federation, Austria, France, United Kingdom, Czechia, Greece, Poland, Estonia, Latvia, Norway
Amgen

Completed

Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Canada, Denmark, Belgium, Hungary, Switzerland, Netherlands, Austria, Czechia, France, United Kingdom, Germany
Amgen

Completed

Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Thrombocytopenia | MDS | Hematology
Amgen

Completed

Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects

Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Amgen

Completed

Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura
Amgen

Active, not recruiting

AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer

United States, Belgium, Austria, Singapore, Taiwan, Japan
Matias Vested

Not yet recruiting

Neuromuscular Monitoring in Children (6 Months - 2 Years) With Electromyography and Acceleromyography

Neuromuscular Blockade

Denmark
Cytokinetics

Withdrawn

Omecamtiv Mecarbil Post-trial Access Study

Chronic Heart Failure With Reduced Ejection Fraction
Amgen

Completed

A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

Chronic Kidney Disease, Secondary Hyperparathyroidism

Belgium, United States, Germany, Poland, United Kingdom, Lithuania
Amgen

Completed

Safety Study of AMG 557 in Subjects With Lupus Arthritis

Lupus Arthritis, Systemic Lupus Erythematosus

United States, Taiwan, Germany, Denmark, Australia, United Kingdom, Malaysia, France
M.D. Anderson Cancer Center
Amgen

Withdrawn

AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Prostate Cancer

United States
Amgen

Terminated

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With Psoriasis

Psoriasis

United States
Amgen

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With Psoriasis

Psoriasis

New Zealand, Australia
Amgen

Completed

Treatment for Patients With Osteoarthritis (OA)

Osteoarthritis
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations

Chronic Lymphocytic Leukemia | Ibrutinib Resistance

United States
Ohio State University Comprehensive Cancer Center

Recruiting

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Bausch Health Americas, Inc.

Terminated

AMG 827 in Subjects With Psoriatic Arthritis

Psoriatic Arthritis

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Amgen

Terminated

Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients

Heart Failure | Healthy Volunteer

France, United States, Netherlands, New Zealand, Germany, Australia, Poland, Canada, Singapore
Vaxon Biotech

Completed

Safety Study of Vx006 Vaccine in Solid Tumor Patients

Solid Tumor

Greece
National Institute of Allergy and Infectious Diseases...

Recruiting

Low Pathogenicity Avian H10N7 Influenza Virus in a Healthy Human Challenge Model

Influenza Infection

United States
Amgen

Completed

A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects

Osteoporosis
Amgen

Recruiting

Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, Germany, Japan, Denmark, Romania, Argentina, Bulgaria, Hungary, Korea, Republic of, Mexico, Poland, Switzerland, Turkey
Amgen
UCB Pharma

Completed

Study of Romosozumab (AMG 785) in Tibial Diaphyseal Fractures Status Post Intramedullary Nailing (STARTT)

Fracture Healing

Canada, Italy, United States, Russian Federation, France, Germany, Hong Kong, Hungary, Australia, Bulgaria, Poland, Romania, Greece, Denmark, Estonia, India, New Zealand, United Kingdom, Latvia, Slovakia, Lithuania, Mexico, Norway
Amgen

Completed

Safety Study of Tezepelumab (AMG 157) in Healthy Adults

Healthy Volunteers
Amgen

Completed

A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis

Postmenopausal Osteoporosis

Korea, Republic of
Amgen

Recruiting

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD (ROCKET-Outpost)

Atopic Dermatitis

United States, Canada
Amgen

Recruiting

Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, Taiwan, Germany, Spain, Turkey, Greece, Japan, Switzerland, Denmark, Korea, Republic of, Austria, Italy, Netherlands, Poland, Romania, Belgium, Argentina, Bulgaria, Czechia, Finland, Hungary, Mexico, Latvia, France, Canada, Slovaki...
Amgen

Completed

Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis

Osteoporosis

United States
Amgen

Terminated

Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis RA

United States, Poland, Germany, Bulgaria, Spain
AbbVie

Active, not recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

Japan
Swiss Group for Clinical Cancer Research

Completed

Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Follicular Lymphoma

Switzerland
AstraZeneca
Parexel

Recruiting

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States (PASSAGE)

Asthma

United States
Amgen

Completed

Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma

Asthma

Canada

Search clinical trials for: AMG 199

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations